Alpha Tau Medical (DRTS) Projected to Announce Quarterly Earnings on Monday

Alpha Tau Medical (NASDAQ:DRTS) is expected to be announcing its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($0.14) per share and revenue of $0.1440 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). On average, analysts expect Alpha Tau Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alpha Tau Medical Price Performance

Shares of NASDAQ:DRTS opened at $11.79 on Monday. The firm has a market cap of $1.06 billion, a P/E ratio of -17.60 and a beta of 1.17. Alpha Tau Medical has a 12-month low of $2.87 and a 12-month high of $14.11. The business has a fifty day simple moving average of $11.24 and a 200 day simple moving average of $8.92. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling at Alpha Tau Medical

In related news, CFO Raphi Levy sold 32,500 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00. Following the completion of the sale, the chief financial officer directly owned 147,680 shares of the company’s stock, valued at approximately $1,599,374.40. This trade represents a 18.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 112,270 shares of company stock valued at $1,270,923. 39.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mariner LLC grew its stake in Alpha Tau Medical by 1.6% in the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after purchasing an additional 1,915 shares during the period. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical during the 3rd quarter worth $62,000. Wells Fargo & Company MN raised its stake in shares of Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after purchasing an additional 17,500 shares during the period. Bank of America Corp DE boosted its holdings in shares of Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Alpha Tau Medical in the 3rd quarter worth about $170,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on DRTS shares. Barclays raised their price objective on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Alpha Tau Medical in a research note on Wednesday, July 22nd. LADENBURG THALM/SH SH lifted their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Finally, Zacks Research lowered Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 1st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.60.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.